Dulaglutide

What is Dulaglutide?

Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist FDA-approved for type 2 diabetes. It consists of a GLP-1 analog fused to a modified IgG4 Fc fragment, which extends its half-life to approximately 5 days. It was the most prescribed GLP-1 agonist worldwide before semaglutide's rise. The REWIND trial demonstrated cardiovascular benefits even in patients without established cardiovascular disease, a distinction from other GLP-1 agonists.

What Dulaglutide Is Investigated For

Dulaglutide is FDA-approved for type 2 diabetes (2014) with a 2020 label expansion for cardiovascular risk reduction in T2D patients with established CV disease or multiple CV risk factors. The strongest evidence is the combined AWARD Phase 3 program (HbA1c reduction of 0.7–1.6 percentage points at 1.5 mg) and the landmark REWIND cardiovascular outcomes trial (9,901 patients, 5.4-year median follow-up) showing a 12% MACE reduction — notably in a population where only 31% had established CV disease at baseline, making it the first GLP-1 agonist with CV benefit demonstrated in a primary-prevention cohort. Renal-protection signals from the REWIND sub-analysis (15% reduction in composite renal outcome, significant reduction in new macroalbuminuria) add a meaningful secondary benefit. The honest framing is that dulaglutide produces modest weight loss (2–5 kg across approved dose range) well below semaglutide (~15%) or tirzepatide (~20%), and is not FDA-approved for weight management — its clinical position is diabetes-first with CV benefit, increasingly displaced by newer agents where weight loss or maximum glycemic effect is the priority.

History & Discovery

Dulaglutide was developed by Eli Lilly as the first long-acting GLP-1 agonist to use an IgG4-Fc fusion architecture — a design choice that departed from the fatty-acid-albumin-binding approach used in liraglutide and later semaglutide. The fusion with a modified human IgG4 Fc fragment via a small peptide linker extends the half-life to approximately 5 days, enabling once-weekly dosing, while the underlying GLP-1 analog carries modifications at positions 8 and 22 for DPP-4 resistance. The FDA approved Trulicity in September 2014 for adults with type 2 diabetes, following the AWARD program of Phase III trials. The AWARD-11 trial later established efficacy and safety at higher doses (3.0 mg and 4.5 mg weekly, approved in 2020), expanding the glycemic and weight-loss effect size. The landmark REWIND cardiovascular outcomes trial (published 2019, n=9,901, median 5.4 years) demonstrated a 12% relative reduction in major adverse cardiovascular events — notably in a population where only 31% had established cardiovascular disease at baseline, making it the first GLP-1 agonist to show CV benefit in a primarily primary-prevention cohort. A 2020 FDA label expansion added reduction of MACE risk in adults with T2D and established CV disease or multiple CV risk factors. Dulaglutide has been among the most prescribed GLP-1 agonists globally but has been increasingly displaced by semaglutide and tirzepatide for both glycemic and body-weight outcomes.

How It Works

Dulaglutide mimics the GLP-1 hormone your gut naturally releases after eating. It tells your pancreas to release more insulin when blood sugar is high, slows stomach emptying so you feel full longer, and reduces appetite signals in the brain.

Dulaglutide is a fusion protein linking a GLP-1 analog (90% homology to native GLP-1, with modifications at positions 8 and 22 for DPP-4 resistance) to a modified human IgG4-Fc heavy chain via a small peptide linker. This design extends the half-life to ~5 days, enabling once-weekly dosing. It activates GLP-1R on pancreatic beta cells (glucose-dependent insulin secretion), alpha cells (glucagon suppression), gastric smooth muscle (delayed emptying), and hypothalamic neurons (appetite suppression). The REWIND trial uniquely demonstrated MACE reduction (12%) in a population where only 31% had established cardiovascular disease, suggesting primary prevention benefit.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Dulaglutide:

• 01Long-term cardiovascular outcomes beyond REWIND's 5.4-year median follow-up — 10-year-plus outcomes data is not yet available.
• 02Comparative effectiveness at the higher 3.0 mg and 4.5 mg doses vs semaglutide and tirzepatide — AWARD-11 established incremental benefit over the 1.5 mg dose but no head-to-head trial has compared 4.5 mg dulaglutide to 2.0 mg semaglutide.
• 03Pediatric long-term data — AWARD-PEDS provided the pediatric approval basis in 2022 but long-duration safety and growth-outcome data in adolescents are still accruing.
• 04Body composition effects during weight loss — less studied than for semaglutide or tirzepatide, though effect size is smaller so clinical relevance may be different.
• 05Post-discontinuation cardiometabolic effects — REWIND and its extension were not designed as discontinuation studies, so the durability of CV benefit after stopping is not characterized.

Forms & Administration

Once-weekly subcutaneous injection via pre-filled single-dose auto-injector pen. Doses: 0.75mg or 1.5mg for type 2 diabetes. Can be administered in abdomen, thigh, or upper arm. No reconstitution or needle handling required. All injectable peptides should only be administered under the guidance of a qualified healthcare provider.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

These doses reflect FDA-labeled protocols for type 2 diabetes. Dulaglutide is not approved for weight management. Individual dosing and continuation decisions require clinician supervision and individualized evaluation.

Timeline of Effects

Common Questions

Who Dulaglutide Is NOT For

Drug & Supplement Interactions

The two principal interaction domains are hypoglycemia risk and altered oral drug absorption. Combined with insulin or insulin secretagogues (sulfonylureas, meglitinides), dulaglutide raises hypoglycemia risk materially, and downward dose adjustment of those agents at initiation and any escalation is typically required. Delayed gastric emptying may alter the rate of absorption of orally administered drugs, though dulaglutide's effect on gastric emptying is somewhat less pronounced than with daily agents or higher-exposure weekly agents — relevant monitoring applies to warfarin (INR after dose changes), levothyroxine (TSH monitoring), and narrow-therapeutic-index oral drugs. Dulaglutide has not shown clinically significant effects on oral contraceptive pharmacokinetics in dedicated studies. Concurrent use with SGLT2 inhibitors, metformin, and DPP-4 inhibitors is well-tolerated and does not require dose adjustment of dulaglutide itself. Ten-plus years of post-marketing pharmacovigilance provide a mature interaction dataset relative to the newer GLP-1 agents.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions